Cynosure Inc. (NASDAQ:CYNO) shares were up 3.6% on Tuesday . The company traded as high as $54.01 and last traded at $53.87, with a volume of 107,306 shares. The stock had previously closed at $52.00.

A number of research analysts recently weighed in on CYNO shares. Zacks Investment Research raised Cynosure from a “sell” rating to a “hold” rating in a research note on Tuesday, April 12th. Brean Capital reaffirmed a “buy” rating and set a $60.00 price target (up from $54.00) on shares of Cynosure in a research note on Thursday, July 28th. Northland Securities set a $60.00 price objective on Cynosure and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Maxim Group increased their price objective on Cynosure from $60.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $62.00 price objective (up from $57.00) on shares of Cynosure in a research note on Wednesday, July 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $59.17.

The stock’s 50-day moving average is $50.72 and its 200-day moving average is $45.43. The firm has a market capitalization of $1.27 billion and a P/E ratio of 64.10.

Cynosure (NASDAQ:CYNO) last posted its earnings results on Tuesday, July 26th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.07. The business earned $110.30 million during the quarter, compared to the consensus estimate of $101.31 million. The firm’s revenue for the quarter was up 31.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 earnings per share. On average, equities research analysts anticipate that Cynosure Inc. will post $1.34 EPS for the current year.

In related news, CEO Michael R. Davin sold 26,271 shares of the firm’s stock in a transaction dated Friday, May 13th. The stock was sold at an average price of $46.59, for a total value of $1,223,965.89. Following the sale, the chief executive officer now directly owns 4,221 shares of the company’s stock, valued at $196,656.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Douglas J. Delaney sold 12,299 shares of the firm’s stock in a transaction dated Friday, May 13th. The stock was sold at an average price of $46.60, for a total value of $573,133.40. Following the completion of the sale, the vice president now directly owns 2,042 shares in the company, valued at $95,157.20. The disclosure for this sale can be found here.

A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers boosted its stake in Cynosure by 7.3% in the fourth quarter. Rhumbline Advisers now owns 29,195 shares of the company’s stock valued at $1,304,000 after buying an additional 1,980 shares during the last quarter. California State Teachers Retirement System boosted its stake in Cynosure by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 41,020 shares of the company’s stock valued at $1,832,000 after buying an additional 646 shares during the last quarter. Lapides Asset Management LLC boosted its stake in Cynosure by 6.4% in the fourth quarter. Lapides Asset Management LLC now owns 58,500 shares of the company’s stock valued at $2,613,000 after buying an additional 3,500 shares during the last quarter. Argent Capital Management LLC boosted its stake in Cynosure by 18.1% in the fourth quarter. Argent Capital Management LLC now owns 92,025 shares of the company’s stock valued at $4,111,000 after buying an additional 14,075 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Cynosure by 9.0% in the fourth quarter. Principal Financial Group Inc. now owns 156,189 shares of the company’s stock valued at $6,977,000 after buying an additional 12,845 shares during the last quarter.

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.